The fucosylation of glycoproteins regulates diverse physiological processes. Inhibitors that can control cellular levels of protein fucosylation have consequently emerged as being of high interest. One area where inhibitors of fucosylation have gained significant attention is in the production of afucosylated antibodies, which exhibit superior antibody-dependent cell cytotoxicity as compared to their fucosylated counterparts. Here, we describe β-carbafucose, a fucose derivative in which the endocyclic ring oxygen is replaced by a methylene group, and show that it acts as a potent metabolic inhibitor within cells to antagonize protein fucosylation. β-carbafucose is assimilated by the fucose salvage pathway to form GDP-carbafucose which, due to its being unable to form the oxocarbenium ion-like transition states used by fucosyltransferases, is an incompetent substrate for these enzymes. β-carbafucose treatment of a CHO cell line used for high-level production of the therapeutic antibody Herceptin leads to dose-dependent reductions in core fucosylation without affecting cell growth or antibody production. Mass spectrometry analyses of the intact antibody and N -glycans show that β-carbafucose is not incorporated into the antibody N -glycans at detectable levels. We expect that β-carbafucose will serve as a useful research tool for the community and may find immediate application for the rapid production of afucosylated antibodies for therapeutic purposes.
We characterized the N-glycosylation profiles of anhydrobiotic tardigrades, R. varieornatus and H. exemplaris, identifying high-mannose, paucimannose, and complex-type oligosaccharides, while hybrid-type glycans were undetectable. Notably, paucimannose-type oligosaccharides accounted for 39% of the N-glycans in R. varieornatus and 17% in H. exemplaris, with a substantial proportion of them exhibiting fucosylation of the innermost GlcNAc via an α1,6-linkage. This core fucosylation pattern, common to all animals, was observed alongside a distinctive glycosylation signature prominently observed in tardigrades: complex-type glycans lacking galactosylation but containing α1,3-fucosylated GlcNAc at non-reducing termini. This structure was more prevalent in H. exemplaris, with 22 out of 87 identified glycoproteins expressing the Fucα1,3-GlcNAc motif, including eight induced during anhydrobiosis. Key glycoproteins such as Cu/Zn-superoxide dismutase and papilin, implicated in oxidative stress protection and extracellular matrix remodeling, were among those modified. Comparative analyses reveal that non-reducing terminal α1,3-fucosylation in tardigrades is distinct from the mammalian Lewis X antigen and similar structures found in invertebrates, suggesting a unique substrate specificity of fucosyltransferases in these species. Genomic analysis identified homologs of Fut9 and FucTC, indicating potential candidates responsible for this glycosylation pattern. Our findings provide new insights into the molecular mechanisms of glycosylation in tardigrades and its relevance to their extreme stress tolerance.
Breast milk oligosaccharides are crucial for neonatal development and health. Yet most milk research focuses on humans, or domesticated mammals that are historically poor in milk oligosaccharide complexity. Here, we perform an exhaustive mass spectrometry-driven structural characterization of milk oligosaccharides in a wild mammal, Atlantic grey seals ( Halichoerus grypus ), throughout their lactation period. Characterizing and quantifying 332 milk oligosaccharides, including 166 novel structures, we reveal seals to rival human milk in complexity, with seal free oligosaccharides reaching unprecedented 28 monosaccharides in size. Glycomics and metabolomics time course analysis establishes a concerted regulatory process reshaping the seal milk glycome throughout lactation,similar as in human milk. Functional analysis of herein newly characterized structures reveals anti-biofilm effects and immunomodulatory functions of seal milk oligosaccharides. We envision these findings to overturn long-held assumptions about milk complexity of non-human mammals and enable insights into the functional relevance of complex carbohydrates in breast milk.
In mammals, the mannose 6-phosphate (M6P) pathway tags newly synthesized hydrolases for delivery to the lysosomes. The pathway underlies healthy lysosomal function, but whether an equivalent system operates outside animals remains largely unexplored. Surveying 53 representative species, across eukaryotic supergroups we show that the M6P receptor (MPR), the phosphorylating enzyme GNPT, and the uncovering enzyme (UCE) form a statistically robust, co-occurring module across extant eukaryotic supergroups. In the human parasite Trichomonas vaginalis , this module has diversified into an expanded MPR family of seven paralogs, the largest reported within these 53 species, alongside a structurally minimal single GNPT gene, despite the complete absence of UCE. Using co-immunoprecipitation (co-IP), mass spectrometry and confocal microscopy, we demonstrate that MPRs and GNPT localise to the Golgi apparatus, and their interactomes show paralog-specific enrichment of distinct hydrolase cargo, adaptor complexes and the retromer complex proteins for retrieval of MPRs, presenting a full receptor-recycling cycle. Critically, mass spectrometry based glycomics directly detects mature M6P-modified N-glycans in T. vaginalis built on unique Man 5 GlcNAc 2 structure with no trace of GlcNAc-capped intermediate, seen in mammalian cells. Together, these results provide evidence that M6P pathway is an ancient and widespread eukaryotic system, with its functionally diversified variant operating in T. vaginalis for lysosomal biogenesis.